Neurogene Inc.
Status: Publicly traded
Direct answer
Neurogene Inc. is publicly traded on NASDAQ under the ticker NGNE.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease)....
Can you invest in Neurogene Inc.?
Yes. Neurogene Inc. trades publicly on NASDAQ as NGNE.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Neurogene Inc.
Detailed equity research is provided by MarketSnap.